These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

908 related items for PubMed ID: 21875334

  • 1. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, Hu W, Yan Y, Feng J, Liao S, Wu P, Wang D, Wang S, Zhou J, Ma D.
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [Abstract] [Full Text] [Related]

  • 2. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q.
    Cancer Lett; 2013 Dec 01; 341(2):231-9. PubMed ID: 23962558
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
    Park J, Park SY, Kim JH.
    Biochim Biophys Acta; 2016 Feb 01; 1863(2):236-43. PubMed ID: 26597704
    [Abstract] [Full Text] [Related]

  • 5. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
    Kandala PK, Srivastava SK.
    BMC Med; 2012 Jan 26; 10():9. PubMed ID: 22280969
    [Abstract] [Full Text] [Related]

  • 6. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC.
    Am J Respir Cell Mol Biol; 2013 Aug 26; 49(2):241-50. PubMed ID: 23526220
    [Abstract] [Full Text] [Related]

  • 7. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X, Shen H, Yin X, Long L, Chen X, Feng F, Liu Y, Zhao P, Xu Y, Li M, Xu W, Li Y.
    Oncotarget; 2017 Jun 13; 8(24):39154-39166. PubMed ID: 28388577
    [Abstract] [Full Text] [Related]

  • 8. A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity.
    Han Z, Hong Z, Chen C, Gao Q, Luo D, Fang Y, Cao Y, Zhu T, Jiang X, Ma Q, Li W, Han L, Wang D, Xu G, Wang S, Meng L, Zhou J, Ma D.
    Carcinogenesis; 2009 Dec 13; 30(12):2014-22. PubMed ID: 19843641
    [Abstract] [Full Text] [Related]

  • 9. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling.
    Yan H, Guo BY, Zhang S.
    Biochem Biophys Res Commun; 2016 Feb 19; 470(4):947-54. PubMed ID: 26826383
    [Abstract] [Full Text] [Related]

  • 10. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
    Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.
    Cancer Biol Ther; 2011 Nov 01; 12(9):837-45. PubMed ID: 21885917
    [Abstract] [Full Text] [Related]

  • 11. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV.
    Clin Cancer Res; 2006 Sep 01; 12(17):5055-63. PubMed ID: 16951221
    [Abstract] [Full Text] [Related]

  • 12. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.
    Int J Cancer; 2013 Jan 15; 132(2):459-71. PubMed ID: 22532243
    [Abstract] [Full Text] [Related]

  • 13. Dual‑regulated oncolytic adenovirus carrying ERCC1‑siRNA gene possesses potent antitumor effect on ovarian cancer cells.
    Zhao T, Ye W, Zhang R, Zhu X, Shi Q, Xu X, Chen W, Xu L, Meng Y.
    Mol Med Rep; 2024 Jul 15; 30(1):. PubMed ID: 38757346
    [No Abstract] [Full Text] [Related]

  • 14. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ, Sun ZL, Wu WG, Xing J, He YF, Xin DM, Han P.
    Genet Mol Res; 2015 Mar 30; 14(1):2450-60. PubMed ID: 25867391
    [Abstract] [Full Text] [Related]

  • 15. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
    Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, Zhang JT, Liu ZM, Cui JR.
    Eur J Med Chem; 2018 Sep 05; 157():887-897. PubMed ID: 30145375
    [Abstract] [Full Text] [Related]

  • 16. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB, Turkson J.
    Oncogene; 2012 May 03; 31(18):2309-22. PubMed ID: 21909139
    [Abstract] [Full Text] [Related]

  • 17. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
    Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, Sohn JH, Park BW, Yun CO.
    Hum Gene Ther; 2006 Apr 03; 17(4):379-90. PubMed ID: 16610926
    [Abstract] [Full Text] [Related]

  • 18. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.
    Gastroenterology; 2012 Mar 03; 142(3):521-530.e3. PubMed ID: 22108192
    [Abstract] [Full Text] [Related]

  • 19. Gene therapy of adenovirus mediated CD ::upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer.
    Wang Z, Cai L, Wang H.
    Gynecol Oncol; 2005 Mar 03; 96(3):643-50. PubMed ID: 15721406
    [Abstract] [Full Text] [Related]

  • 20. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
    Yu T, Yang Y, Zhang J, He H, Ren X.
    Eur J Pharm Biopharm; 2015 Apr 03; 91():103-10. PubMed ID: 25668779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.